Quick Answer
Nurix Therapeutics, Inc. reported Earnings Per Share Diluted of $3.05 (loss) per share for the year ending 2025.
- Nurix Therapeutics, Inc. showed a decrease of -5.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.00 per share | Q2 2021: $0.60 (loss) per share | Q3 2021: $0.65 (loss) per share | Q1 2022: $0.95 (loss) per share | Q2 2022: $1.01 (loss) per share | Q3 2022: $0.90 (loss) per share | Q1 2023: $0.75 (loss) per share | Q2 2023: $0.45 (loss) per share | Q3 2023: $0.68 (loss) per share | Q1 2024: $0.76 (loss) per share | Q2 2024: $0.71 (loss) per share | Q3 2024: $0.67 (loss) per share | Q1 2025: $0.67 (loss) per share | Q2 2025: $0.52 (loss) per share | Q3 2025: $1.03 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Nurix Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 11.7%.
- Historical annual values: Fiscal year 2025: $3.05 (loss) per share | Fiscal year 2024: $2.88 (loss) per share | Fiscal year 2023: $2.65 (loss) per share | Fiscal year 2022: $3.71 (loss) per share | Fiscal year 2021: $2.73 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: